CAMP4 Therapeutics Corporation Income Tax Examination, Penalties and Interest Expense
CAMP4 Therapeutics Corporation (CAMP) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-21.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2024-11-21
- CAMP4 Therapeutics Corporation income tax examination, penalties and interest expense for the quarter ending 2024-09-30 was $0.00.
- CAMP4 Therapeutics Corporation income tax examination, penalties and interest expense for the quarter ending 2023-09-30 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 3 month | Income Tax Examination, Penalties and Interest Expense 9 month |
|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-21 | $0.00 10-Q · filed 2024-11-21 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-21 | $0.00 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |